|Videos|April 26, 2023
Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc
Author(s)Peter J. Goadsby, MD, PhD, DSc
The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]
Advertisement
WATCH TIME: 5 minutes
"Half the patients are losing half of their disabling migraine attacks, despite the fact that there's a group of patients who came into this study had failed preventives, up to four preventives, in the past. It's really important from a clinical practice point of view because these are the sort of patients who we see in our practice every day."
At the 2023 American Academy of Neurology (AAN) Annual Meeting , April 22-27, in Boston, Massachusetts, positive data from the phase 3 global, randomized, double-blind, placebo-controlled trial ELEVATE (NCT04740827) was presented, assesing atogepant for the prevention of episodic migraine in adult patients who had previously failed 2 to 4 classes of oral preventive medications.3 In the trial, the primary end point was the change from baseline in mean monthly migraine days (MMDs) across the span of 12 weeks, while secondary end points looked at the achievement of more than 50% reduction in MMDs, change from baseline in MMDs, and change from baseline in acute medication use days.
REFERENCES
1. FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine. News release. AbbVie. September 28, 2021. Accessed April 26, 2023. https://news.abbvie.com/news/press-releases/fda-approves-qulipta-atogepant-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-preventive-treatment-migraine.htm?view_id=1531
2. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine. News release. AbbVie. April 23, 2023. Accessed April 26, 2023. https://news.abbvie.com/article_display.cfm?article_id=12576
3.Pozo-Rosich P. Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial. Presented at: 2023 AAN Annual Meeting; April 22-27, Boston, Massachusetts. Abstract 007. Emerging Science session.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD
5